Abstract P3-06-10: Immune-related adverse events (irAEs) and pathological complete response (pCR) rates in patients receiving neoadjuvant chemotherapy (CHT) and pembrolizumab (PEM) for early triple-negative breast cancer (eTNBC)

Maximilian Marhold, Rupert Bartsch, Kerstin Wimmer et al.|Cancer Research|2023

Cited by 2